PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Founded entity Vor Bio, a clinical stage cell and genome engineering company, has received new clinical data from ongoing Phase 1/2 VBP101 study. The study looks at patients with relapsed or refractory acute myeloid leukaemia receiving trem-cel followed by the Mylotarg drug. Recent data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.

Current stock price: 148.60 pence

12-month change: down 25%

Copyright 2024 Alliance News Ltd. All Rights Reserved.